CN115485276A - 氘代akt激酶抑制剂 - Google Patents

氘代akt激酶抑制剂 Download PDF

Info

Publication number
CN115485276A
CN115485276A CN202180032532.1A CN202180032532A CN115485276A CN 115485276 A CN115485276 A CN 115485276A CN 202180032532 A CN202180032532 A CN 202180032532A CN 115485276 A CN115485276 A CN 115485276A
Authority
CN
China
Prior art keywords
compound
formula
protecting group
compounds
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180032532.1A
Other languages
English (en)
Inventor
马昌友
田禾
赵建良
余方丹
吴杏森
陈东晖
吴舰
徐丹
朱春霞
田舟山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Original Assignee
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd filed Critical Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Publication of CN115485276A publication Critical patent/CN115485276A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本公开涉及氘代AKT激酶抑制剂，具体地，涉及式I所示的化合物，或其药学上可接受的盐。本发明还提供了其制备方法，以及用于预防和/或治疗AKT蛋白激酶介导的疾病的用途。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202180032532.1A 2020-05-15 2021-05-14 氘代akt激酶抑制剂 Pending CN115485276A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010415312 2020-05-15
CN2020104153124 2020-05-15
PCT/CN2021/093813 WO2021228223A1 (zh) 2020-05-15 2021-05-14 氘代akt激酶抑制剂

Publications (1)

Publication Number Publication Date
CN115485276A true CN115485276A (zh) 2022-12-16

Family

ID=78525343

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032532.1A Pending CN115485276A (zh) 2020-05-15 2021-05-14 氘代akt激酶抑制剂

Country Status (2)

Country Link
CN (1) CN115485276A (zh)
WO (1) WO2021228223A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882347A (zh) * 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
CN101631778A (zh) * 2006-07-06 2010-01-20 阵列生物制药公司 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
CN102574852A (zh) * 2009-10-23 2012-07-11 伊莱利利公司 Akt抑制剂
CN108373476A (zh) * 2017-01-13 2018-08-07 成都地奥制药集团有限公司 一种激酶抑制剂及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1673092E (pt) * 2003-10-17 2007-11-23 4 Aza Ip Nv ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
DE602007011628D1 (de) * 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8329709B2 (en) * 2008-01-09 2012-12-11 Genentech, Inc. 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors
ES2620119T3 (es) * 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
CA3127884A1 (en) * 2019-01-29 2020-08-06 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Akt inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882347A (zh) * 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
CN101631778A (zh) * 2006-07-06 2010-01-20 阵列生物制药公司 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
CN102574852A (zh) * 2009-10-23 2012-07-11 伊莱利利公司 Akt抑制剂
CN108373476A (zh) * 2017-01-13 2018-08-07 成都地奥制药集团有限公司 一种激酶抑制剂及其制备和应用

Also Published As

Publication number Publication date
WO2021228223A1 (zh) 2021-11-18

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
RU2759678C2 (ru) Соединения и композиции в качестве ингибиторов эндосомальных toll-подобных рецепторов
CN113272304B (zh) Akt抑制剂
AU2011256380B2 (en) Macrocyclic compounds as Trk kinase inhibitors
EP4026832A1 (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7
IL262345A (en) Inhibitors of the kinase-like activin receptor
ES2654288T3 (es) Moduladores de P2X7
WO2016007185A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
AU2013290054A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
KR20190067913A (ko) 신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물
CA2963051A1 (en) Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
CA3071032A1 (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
WO2011152485A1 (ja) 新規４，５－縮環ピリミジン誘導体
WO2020221294A1 (zh) 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
CA3217830A1 (en) 2-aminobenzothiazole compounds and methods of use thereof
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
CA3200620A1 (en) Aromatic heterocyclic compound, and pharmaceutical composition and application thereof
CN117177744A (zh) Cdk2抑制剂及其使用方法
EP3230288A1 (en) Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
CN115485276A (zh) 氘代akt激酶抑制剂
CN114591321A (zh) 氮杂并环化合物、其制备方法及其用途
CN117964620A (zh) Akt抑制剂
WO2022017446A1 (zh) Akt抑制剂的单位剂量组合物
WO2024086939A1 (en) Purine compounds, compositions comprising them and uses thereof
US20240034731A1 (en) Aza-quinazoline compounds and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination